Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AC ImmuneACIU +9.43%49 EV-to-OCF is -3.17 as of Aug. 22, 2026. GuruFocus rates ACIU with a GF Score™ of 49/100 and a GF Value™ of $3.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,407 Biotechnology companies, AC Immune ranks worse than 54.58% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, AC Immune's Enterprise Value is $199.23 Mil.
AC Immune's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-62.93 Mil. Therefore, AC Immune's EV-to-OCF for today is -3.17.
The historical rank and industry rank for AC Immune's EV-to-OCF or its related term are showing as below:
ACIU'
s EV-to-OCF Range Over the Past 10 Years
Min: -154.62 Med: -2.56 Max: 36.21
Current: -3.17
During the past 12 years, the highest EV-to-OCF of AC Immune was 36.21. The lowest was -154.62. And the median was -2.56.
ACIU's EV-to-OCF is ranked worse than 54.58% of 1407
companies
in the Biotechnology industry
Industry Median: -3.61
vs ACIU: -3.17
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AC Immune's share price for today is $2.90.
AC Immune's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.543.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AC Immune EV-to-OCF Related Terms
AC Immune EV-to-OCF Historical Data
* Premium members only.
The historical data trend for AC Immune's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AC Immune's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AC Immune EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AC Immune's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where AC Immune's EV-to-OCF falls into.
AC Immune's current Enterprise Value is $199.23 Mil.
AC Immune's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AC Immune (ACIU) has a EV-to-OCF of -3.17 as of Aug. 22, 2026. According to the industry distribution chart, AC Immune ranks #768 out of 1407 companies in the Biotechnology industry, placing it in the top 54.6%.
Is AC Immune's EV-to-OCF too high?
AC Immune's current EV-to-OCF is -3.17. Based on the distribution chart, AC Immune ranks #768 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AC Immune has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's EV-to-OCF compare to TRDA and TARA?
According to the Biotechnology industry distribution chart, AC Immune ranks #768 out of 1407 companies for EV-to-OCF. This places AC Immune in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. AC Immune's current EV-to-OCF is -3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.41, compared to a current price of $2.90 — trading 15% below its estimated fair value. The current EV-to-OCF is -3.17. AC Immune's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For AC Immune (ACIU), the current EV-to-OCF is -3.17 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AC Immune (ACIU) Overvalued in 2026?
Based on GuruFocus' analysis, AC Immune stock appears to be undervalued.
The current stock price of $2.90 is trading 15% below its estimated GF Value™ of $3.41.
GuruFocus considers AC Immune to be Modestly Undervalued.
Key valuation signals for ACIU:
EV-to-OCF: -3.17
GF Value™: $3.41 vs. price of $2.90 (15% below fair value)
No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
49GF Score
Get the complete analysis for ACIU
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIU has been successfully added to your 
